Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (AI000752-19)
Received: 28 May 2020
Accepted: 29 May 2020
First Online: 9 June 2020
Ethics approval and consent to participate
: Human brain samples were obtained either from the National CJD Research & Surveillance Unit Brain and Tissue Bank, which is part of the MRC Edinburgh Brain & Tissue Bank (Edinburgh Brain Bank 16-ES-0084), UK, or from the University of Verona, Italy. These latter tissues were obtained at autopsy and sent to the Neuropathology Unit at the University of Verona for statutory definite diagnosis of CJD. Ethical approval for the acquisition and use of post-mortem human CJD brain samples was obtained from the National Institutes of Health (NIH) Office of Human Subject Research (Exempt #11763 and #12725) and no patient identifiable data was transferred to the NIH.The animal experimental protocol was reviewed and approved by the Rocky Mountain Laboratories Animal Care and Use Committee. This study was carried out in strict accordance with the recommendations in the <i>Guide for the Care and Use of Laboratory Animals</i> of the National Institutes of Health.
: Not applicable.
: The authors declare that they have no competing interests.